burning mouth
Recently Published Documents


TOTAL DOCUMENTS

1031
(FIVE YEARS 335)

H-INDEX

55
(FIVE YEARS 6)

2021 ◽  
Vol 8 (2) ◽  
pp. 18
Author(s):  
Nendika Dyah Ayu Murika Sari ◽  
Rochman Mujayanto

2021 ◽  
pp. 381-385
Author(s):  
Assunta PATANO ◽  
Daniela DI VENERE ◽  
Sabino CECI ◽  
Pula BERATE ◽  
Sebastian CANDREA ◽  
...  

Introduction. Burning mouth syndrome (BMS) is a clinical condition characterized by the presence of chronic pain in absence of clinically visible lesions of the oral mucosa. The etiology is uncertain and the therapeutic strategies still controversial. The objective of this prospective study is to analyze the efficacy of essential oils-based mouthwashes in the therapy of BMS. Material and method. This study included 16 patients affected by BMS who were treated with essential oils-based mouthwashes and glucose solution on alternated days for 30 days. Symptomatology was evaluated after 15, 30 and 90 days. Results and discussions. A the end of the treatment, most of the patients (67%) referred an improvement of symptoms up to complete remission in 90 days. Conclusions. Based on this study, essential oils-based mouthwashes could represent a valid aid in the treatment of BMS. Further studies are necessary in order to identify effective and standardized therapeutic protocols. Keywords: Burning Mouth Syndrome; oral rinse; essential oils; therapeutic strategies,


Author(s):  
Tahereh Nosratzehi

Abstract Burning mouth syndrome (BMS) is described by an intense burning sensation of the tongue or other oral areas without a clear etiopathology. The diagnosis of BMS is challenging due to variations of manifestations. The management of BMS is complicated due to the complex etiology of the disease. Many medications and treatment methods have been recommended for BMS management, but no one confirmed as the standard method. In this study, the therapeutic approaches of BMS were evaluated. The data of the article was obtained from PubMed/MEDLINE, Cochrane Library, and Web of Science. The following terms including “burning mouth syndrome”, “therapy”, and “treatment” were used for search in the databases. A wide range of articles about the therapeutic approach of BMS was searched and reviewed. Pharmacological and non-pharmacological approaches have been used for BMS management. Pharmacological treatments are including Capsaicin, Clonazepam, Low-dose aripiprazole, Alpha-lipoic acid, Duloxetine, Amitriptyline, Gabapentin, and Pregabalin, and ultra-micronized palmitoylethanolamide. Non-pharmacological therapies for BMS are cognitive therapy, Electroconvulsive therapy, Laser therapy, Acupuncture and auriculotherapy, Transcranial Magnetic Stimulation (rTMS), Salivary Mechanical Stimulation, and Botulinum Toxin. A detailed assessment of the etiology and pathophysiology of BMS, and having information about novel therapeutic interventions are essential for the management of BMS.


2021 ◽  
Vol 11 (23) ◽  
pp. 11538
Author(s):  
Francisco José Sánchez-Cuesta ◽  
Yeray González-Zamorano ◽  
Aida Arroyo-Ferrer ◽  
Martín Avellanal ◽  
Josué Fernández-Carnero ◽  
...  

Burning Mouth Syndrome (BMS) is a multifactorial, chronic pain condition with neuropathic and psychogenic mechanisms. Cortical activation as well as sustained attention and executive functions have proven to be affected by chronic pain. The main objectives of this work were to test the efficacy of a multidimensional personalized pain treatment protocol and to investigate if the effects are based on psychophysical pain processing changes or cognitive effects. A 74-year-old female with 2 years of BMS received 10 sessions of a combined protocol of anodal left dorsolateral prefrontal cortex tDCS, cognitive therapy, and therapeutic exercise. The subjective perception of pain decreased by 47% after treatment but returned to the baseline at 45 days. No changes were found in objective pain measurements apart from a transient worsening of conditioned pain modulation. A large effect size was found in all functional scales, processing speed and executive control as well as sustained attention that persisted during follow-up. No changes in anxiety and depression were found. A multimodal therapeutic approach combining TDCS, cognitive rehabilitation and therapeutic exercise produces improved quality of life, disability and pain perception correlated with improvements in processing speed, executive control and sustained attention but independent of changes in psychophysical pain processing.


2021 ◽  
Vol 53 ◽  
pp. S325-S326
Author(s):  
N. Cunha E Costa ◽  
R. Diniz Gomes ◽  
S.P. Cruz ◽  
T. Mendonça ◽  
G. Sobreira

Author(s):  
Yu-Hsueh Wu ◽  
Ying-Tai Jin ◽  
Yang-Che Wu ◽  
Julia Yu-Fong Chang ◽  
Chun-Pin Chiang ◽  
...  

Author(s):  
Milica Petrović ◽  
Ljiljana Kesić ◽  
Katarina Šavikin ◽  
Bojana Miladinović ◽  
Radmila Obradović ◽  
...  

Pharmaceutics ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1838
Author(s):  
Reem Hanna ◽  
Snehal Dalvi ◽  
Rene Jean Bensadoun ◽  
Judith E. Raber-Durlacher ◽  
Stefano Benedicenti

Mitochondrial homeostasis is crucial for energy production and neuronal survival in neurological primary burning mouth syndrome (npBMS). Photobiomodulation therapy (PBMT) has been utilised in npBMS management, however, its role of intervention remains controversial. The aim of this systematic review and meta-analysis of CRD 42020198921 PROSPERO registration reference was to oversee and determine the efficacy of PBMT in patients with npBMS, identifying the gaps and bridge them by proposing recommendations for future studies purposes. PRISMA guidelines and Cochrane Collaboration recommendations followed. Various search engines employed to analyse a total of 351 studies of which 12 were included. A wide range of utilised PBM wavelengths was between 635–980 nm and the power output ranged between 30 mW and 4000 mW. A high risk of bias (RoB) was noted in 7 out of 12 included studies (58.3%), as results of qualitative analysis. Meta-analysis findings of 4 out of 12 studies showed statistically significant intergroup differences (SSID) for visual analogue scale (VAS) values (MD = −1.47; 95% CI = −2.40 to −0.53; Z = 3.07 (p = 0.002) whereas meta-analysis on 5 out of 12 studies revealed SSID for anxiety/depression and quality of life (MD = −1.47; 95% CI = −2.40 to −0.53; Z = 3.07 (p = 0.002), favouring PBMT group to the control treatment strategies. Despite the inconsistency and diversity in PBM parameters (wavelength, power, light source, spot size, emission mode, energy per point, total energy) and treatment protocols (exposure time, number of sessions, time interval between sessions, treatment duration)—majority of the included studies showed positive PBM results. The high RoB and meta-analytical heterogeneity in the eligible studies warrant the necessity to perform well-designed and robust RCTs after acknowledging the drawbacks of the available scientific literature and addressing our suggested recommendations highlighted in our review.


2021 ◽  
Vol 14 (6) ◽  
pp. 1589-1590
Author(s):  
Francisco José Sánchez Cuesta ◽  
Yeray González Zamorano ◽  
Aida Arroyo Ferrer ◽  
Josué Fernández Carnero ◽  
Juan Pablo Romero Muñoz

Sign in / Sign up

Export Citation Format

Share Document